Hyperaldosteronism is associated with impaired vascular reactivity; however, the mechanisms by which aldosterone promotes endothelial dysfunction remain unknown. Glucose-6-phosphate dehydrogenase (G6PD) modulates vascular function by limiting oxidant stress to preserve bioavailable nitric oxide (NO ). Here we show that aldosterone (10 -9 -10 -7 mol/l) decreased endothelial G6PD expression and activity in vitro, resulting in increased oxidant stress and decreased NO levels-similar to what is observed in G6PD-deficient endothelial cells. Aldosterone decreased G6PD expression by increasing expression of the cyclic AMPÀresponse element modulator (CREM) to inhibit cyclic AMPÀresponse element binding protein (CREB)-mediated G6PD transcription. In vivo, infusion of aldosterone decreased vascular G6PD expression and impaired vascular reactivity. These effects were abrogated by spironolactone or vascular gene transfer of G6pd. These findings demonstrate that aldosterone induces a G6PD-deficient phenotype to impair endothelial function; aldosterone antagonism or gene transfer of G6pd improves vascular reactivity by restoring G6PD activity.
Hyperaldosteronism is associated with impaired vascular reactivity; however, the mechanisms by which aldosterone promotes endothelial dysfunction remain unknown. Glucose-6-phosphate dehydrogenase (G6PD) modulates vascular function by limiting oxidant stress to preserve bioavailable nitric oxide (NO ). Here we show that aldosterone (10 -9 -10 -7 mol/l) decreased endothelial G6PD expression and activity in vitro, resulting in increased oxidant stress and decreased NO levels-similar to what is observed in G6PD-deficient endothelial cells. Aldosterone decreased G6PD expression by increasing expression of the cyclic AMPÀresponse element modulator (CREM) to inhibit cyclic AMPÀresponse element binding protein (CREB)-mediated G6PD transcription. In vivo, infusion of aldosterone decreased vascular G6PD expression and impaired vascular reactivity. These effects were abrogated by spironolactone or vascular gene transfer of G6pd. These findings demonstrate that aldosterone induces a G6PD-deficient phenotype to impair endothelial function; aldosterone antagonism or gene transfer of G6pd improves vascular reactivity by restoring G6PD activity.
Hyperaldosteronism has been associated with impaired vascular reactivity in individuals with an aldosterone-producing adrenal adenoma, hypertension or congestive heart failure 1,2 , which is improved markedly following surgical resection of the adenoma 3 or treatment with spironolactone 4 . The mechanisms by which aldosterone adversely influences vascular reactivity remain to be elucidated; however, it has been suggested that aldosterone initiates these pathological effects by inducing a vasculopathy characterized by increased vascular reactive oxygen species (ROS) and decreased endothelium-derived bioavailable nitric oxide (NO ) 5 .
Glucose-6-phosphate dehydrogenase (G6PD), the first and rate-limiting enzyme in the pentose phosphate pathway, is the principal intracellular source of the reduced form of nicotinamde adenine dinucleotide phosphate (NADPH). NADPH serves as a reducing equivalent to limit ROS and maintain levels of reduced glutathione (GSH) 6 . Thus, G6PD is a critical determinant of the intracellular redox state and provides a redox environment that favors NO . When G6PD activity is deficient, endothelial cells challenged with oxidants demonstrate increased ROS and decreased GSH stores 6 , whereas cells that overexpress G6PD remain resistant to redox imbalance 7 . G6PD-derived NADPH also serves as a cofactor for the endothelial isoform of nitric oxide synthase (eNOS). The importance of G6PD for eNOS activity is revealed when NADPH stores are depleted: eNOS uncouples and generates superoxide in preference to NO (ref. 6) . In contrast, overexpression of G6PD increases eNOS activity and augments NO formation 7 .
Early studies showed that specific glucocorticoid, mineralocorticoid and sex steroid compounds can inhibit G6PD activity 8 . Although the effect of aldosterone on G6PD activity was not evaluated, dehydroepiandrosterone, which is structurally similar to aldosterone, was found to be a potent inhibitor of G6PD (ref. 8) . Notably, aldosterone has been shown to decrease G6PD activity in rat myocardial homogenates when injected twice daily for 17 d (ref. 9) . Taken together, these studies raise the possibility that aldosterone may induce a G6PD-deficient state to promote vascular dysfunction. To date, there have been no studies to our knowledge that have examined the effects of aldosterone on G6PD and the consequences for endothelial function and vascular reactivity.
RESULTS
To evaluate the effects of aldosterone on G6PD, we exposed bovine aortic endothelial cells (BAEC) to aldosterone (10 -9 -10 -7 mol/l) for 12-48 h and examined mineralocorticoid receptor (MR) expression, G6PD expression and G6PD activity. Aldosterone did not influence MR expression (Fig. 1a) ; however, by 24 h, aldosterone-treated cells demonstrated a concentration-dependent decrease in G6PD protein expression (Fig. 1b) and G6pd mRNA levels (Fig. 1c,d) , resulting in decreased G6PD activity (Fig. 1e) and NADPH levels (Fig. 1f) compared to vehicle-treated cells. As we saw no further decrease in © 2007 Nature Publishing Group http://www.nature.com/naturemedicine G6PD at the 36-h time point, we elected to perform experiments following a 24-h incubation period. To demonstrate that these findings were not unique to BAEC, we performed similar experiments in human coronary artery endothelial cells; exposure to aldosterone resulted in a similar decrease in G6PD protein expression, mRNA levels and activity ( Supplementary Fig. 1 online) .
Protein kinase A activation decreases G6PD expression To determine the mechanism by which aldosterone decreased G6PD expression, we next examined cAMP levels and protein kinase A (PKA) activity, as PKA activation has been associated with decreased G6PD activity 10, 11 . Exposure to aldosterone increased cyclic AMP (cAMP) levels and PKA activity despite similar PKA protein levels among treatment groups ( Supplementary Fig. 2 online) . PKA activation, in turn, increased phosphorylation of cyclic AMP-response element binding protein (CREB) at Ser133, but not levels of total CREB or CREB-binding protein (Fig. 2a) .
Although activation of CREB is associated with an upregulation of gene transcription, in aldosterone-treated cells we observed a downregulation of G6pd mRNA. We therefore examined expression of the cyclic AMP-response element modulator (CREM), an endogenous inhibitor of gene transcription driven by CREB (ref. 12 ) and found that CREM protein expression (Fig. 2b ) and mRNA levels (Fig. 2c) were increased in aldosterone-treated cells. We next performed a nuclear run-on assay using nuclei isolated from cells exposed to aldosterone that were transfected with siRNA targeted to Creb or Crem ( Supplementary Fig. 2) ; this experiment demonstrated that CREM, but not CREB, modulated inhibition of G6pd gene transcription. In the presence of aldosterone, cells transfected with Creb siRNA, which decreased CREB expression by 72%, showed no difference in G6pd gene transcription as compared to vehicle-treated cells. In contrast, when CREM expression was downregulated by 66%, G6PD expression was restored to levels similar to those observed in vehicletreated cells ( Supplementary Fig. 3 online and Fig. 2d) .
We next determined that increased CREM expression was dependent upon PKA activation. We treated cells with aldosterone in the presence of the specific cell-permeable PKA inhibitor 14-22 amide (PKI) (10 mmol/l). PKI inhibited PKA activity ( Supplementary Fig. 2 ), resulting in decreased CREM protein and mRNA levels (Fig. 2b,c) and increased G6PD protein expression in aldosterone-treated cells ( Supplementary Fig. 2 ), despite decreased CREB phosphorylation (Fig. 2a) . We observed similar effects when we inhibited MR activation by treating cells with spironolactone (10 mmol/l) ( Supplementary Fig. 2 and Fig. 2a-c) . To confirm that these effects were mediated by activation of PKA and not other kinases known to activate CREB, we examined expression of mitogen-and stress-activated protein kinase (MSK), Ca 2+ -calmodulin kinase (CAMK), p90 ribosomal S6 kinase (RSK) and p44/42 mitogen-activated protein kinase (MAPK) and found no difference in expression between treatment groups. Furthermore, we found no difference in serum-glucocorticoid kinase (SGK), phospho-SGK or SGK activity between vehicle-treated and aldosteronetreated cells ( Supplementary Fig. 4 online) .
Next, we determined the mechanism by which aldosterone decreases G6PD expression using human coronary artery endothelial cells. We examined a 1-kb segment of the G6pd promoter upstream of the transcription start site, in order to identify CREB binding sequences. We identified a single site (À889 to À881) containing the sequence 5¢-TGACGATA-3¢, which has been confirmed 13 and reported to bind both CREB and CREM (ref. 14). We performed a mobility shift assay to demonstrate that CREB/CREM protein-DNA binding occurred in aldosterone-treated cells at this site (Fig. 2e) . In vehicle-treated cells, a specific protein-DNA complex was present that was abolished in the presence of excess unlabeled oligonucleotide. A CREB antibody supershifted this complex, whereas incubation with a CREM antibody did not produce this effect. In contrast, in aldosterone-treated cells, there was evidence of supershift by both CREB and CREM antibodies. In addition, we assessed other downstream effects of CREB activation by examining DNA binding to the nuclear factor kappa B (NF-kB) and activating transcription factor-2 (ATF-2); there was no difference observed between aldosterone-treated and vehicletreated cells ( Supplementary Fig. 4) .
We also performed chromatin immunoprecipitation assays to confirm the association of CREB and CREM with the G6pd promoter. In vehicle-treated cells, only CREB was associated with this promoter; in contrast, in aldosterone-treated cells, both CREB and CREM were associated (Fig. 2f) . Both PKA inhibition with PKI and MR inhibition with spironolactone completely blocked the aldosterone-mediated recruitment of CREM to the promoter.
Aldosterone modulates oxidant stress and NO levels To determine the consequences of the aldosterone-induced G6PD-deficient phenotype on ROS accumulation, we measured 6-carboxy-2'-7'-dichlorodihydrofluorescein fluorescence as a nonspecific marker of oxidant stress. As compared to vehicle-treated cells, cells exposed to aldosterone demonstrated increased ROS levels (Fig. 3a) , mostly derived from eNOS and NADPH oxidase ( Supplementary Fig. 5 online), which were associated with a concomitant decrease in the GSH to oxidized glutathione (GSSG) ratio (Fig. 3b) . We next examined eNOS activity in aldosterone-treated BAEC in the absence of exogenous cofactors. Compared to vehicle-treated cells, eNOS activity was decreased significantly (P o 0.001) in aldosteronetreated cells (10 -7 mol/l). This decrease did not result from a decrease in eNOS expression (Fig. 3c,d) ; however, there was a shift in the eNOS monomer/dimer ratio, which has been associated with eNOS uncoupling (refs. 15,16 and Fig. 3d ). To demonstrate that the observed decrease in eNOS activity resulted from depleted NADPH stores owing to decreased G6PD activity, we measured eNOS activity in cell homogenates in the presence of exogenous NADPH and found that eNOS activity in aldosterone-treated cells was similar to that observed in vehicle-treated cells (872 ± 46 versus 923 ± 62 c.p.m., P ¼ NS, n ¼ 4).
Next, we examined cGMP levels as a measure of bioavailable NO . In unstimulated cells, cGMP levels were decreased in aldosteronetreated (10 -7 
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G6PD-deficient endothelial cells and aldosterone
To confirm that aldosterone increased ROS and decreased eNOS activity by inhibiting G6PD, we examined these parameters in G6PD-deficient endothelial cells isolated from aortas of G6PD-deficient male mice 17 . Under basal conditions, G6PD activity (32.6 ± 6.1 versus 128.4 ± 12.8 units/6 min/mg protein, P o 0.01, n ¼ 8) and NADPH levels (1.0 ± 0.04 versus 2.1 ± 0.03 mmol/l/mg protein, P o 0.01, n ¼ 4) were decreased significantly in G6PD-deficient cells compared to those in cells isolated from C3H wild-type mice. G6PD-deficient cells were characterized further by increased ROS levels (132.3 ± 4.9 versus 44.4 ± 5.1 fluorescence units, P o 0.01, n ¼ 8), decreased eNOS activity (402.2 ± 22.9 versus 998.9 ± 33.3 c.p.m., P o 0.01, n ¼ 3) and decreased acetylcholine (1 mmol/l)-stimulated cGMP levels (0.8 ± 0.2 versus 2.7 ± 0.1 pmol cGMP/mg protein, P o 0.01, n ¼ 4), as compared to wild-type cells. Whereas exposure to aldosterone decreased G6PD activity in wildtype cells, there was no further decrease in activity in G6PD-deficient cells (41.5 ± 3.2 versus 46.4 ± 6.5 units/6 min/mg protein, P ¼ NS, n ¼ 8). Furthermore, aldosterone (10 -7 mol/l) did not increase ROS levels (126.4 ± 9.8 versus 131.4 ± 15.0 fluorescence units, P ¼ NS, n ¼ 8), decrease eNOS activity (388.4 ± 36.0 versus 369.6 ± 43.2 c.p.m., P ¼ NS, n ¼ 3) or decrease acetylcholine (1 mmol/l)-stimulated cGMP levels (0.7 ± 0.2 versus 0.7 ± 0.1 pmol cGMP/mg protein, P ¼ NS, n ¼ 4) in G6PD-deficient cells, suggesting that aldosteroneinduced decreased G6PD expression is the cause, and not the consequence, of increased ROS and diminished NO levels.
MR blockade or G6pd gene transfer limits G6PD inhibition
To determine if aldosterone antagonism would prevent aldosteronemediated inhibition of G6PD, we co-incubated aldosterone-treated (10 À7 mol/l) BAEC with spironolactone (10 mmol/l). Spironolactone prevented the aldosterone-mediated decrease in G6PD expression ( Supplementary Fig. 2 ), G6PD activity and NADPH levels (Supplementary Fig. 6 online) . Spironolactone also limited ROS accumulation and increased both eNOS activity ( Supplementary Fig. 6 ) and cGMP levels (0.6 ± 0.2 versus 1.8 ± 0.2 pmol cGMP/mg protein, P o 0.01, n ¼ 4).
We next sought to determine if increased G6PD activity would offer a protective benefit for BAEC exposed to aldosterone. Accordingly, we infected BAEC with an adenoviral vector encoding G6pd (AdG6pd) at a multiplicity of infection (MOI) of 10 pfu/cell or with an empty vector as a control 7 . Infection of BAEC with AdG6pd increased G6PD expression 310%, G6PD activity 500% and NADPH levels 46%, compared to control cells ( Supplementary Fig. 7 online) . Furthermore, cells that overexpressed G6PD maintained G6PD expression, G6PD activity and NADPH levels ( Supplementary Fig. 7 ) following a 24-h exposure to aldosterone and were resistant to aldosteroneinduced ROS accumulation and inhibition of eNOS activity (Supplementary Fig. 7 ) as compared to control cells.
Aldosterone decreases G6PD activity in vivo
To determine if our in vitro findings were operative in vivo, we implanted osmotic minipumps to infuse either aldosterone (50 mg/kg/d) (n ¼ 40) or vehicle (n ¼ 40) for 14 d in C3H wildtype mice. Aldosterone infusion increased systolic blood pressure after 4 d, and it remained elevated for the 14-d treatment period (Fig. 4a) . Compared to vehicle-infused mice, aldosterone infusion resulted in a marked increase in serum aldosterone levels at day 14 (622 ± 27 versus 4,193 ± 55 pmol/l, P o 0.001, n ¼ 12), which was associated with a decrease in aorta G6PD expression (Fig. 4b), G6PD activity (Fig. 4c) and NADPH levels (Fig. 4d) .
We next examined aorta ROS using dihydroethidine staining (Fig. 4e) . In aortas harvested from aldosterone-infused mice, there was an increase in intima and medial ROS suggesting an increase in both endothelial and vascular smooth muscle oxidant stress that was not observed in vehicle-treated mice; this finding was confirmed with lucigenin (5 mmol/l) chemiluminescence (Fig. 4f) . We also found a significant (P o 0.01) reduction in aorta cGMP levels in aldosteroneinfused as compared to vehicle-infused mice (Fig. 4g) , despite similar levels of eNOS expression in both groups (Fig. 4h ).
Aldosterone and vascular reactivity
We evaluated vascular reactivity in vivo, in order to examine the functional consequences of aldosterone-mediated decreased vascular G6PD activity. We used intravital videomicroscopy to examine the response of mesenteric resistance vessels to the endotheliumdependent vasodilator acetylcholine (10 -9 -10 -5 mol/l) (Fig. 5a ).
Compared to vehicle-infused mice (n ¼ 12), aldosterone-infused mice (n ¼ 12) demonstrated a significant (P o 0.03) impairment of endothelium-dependent vasodilation. Similarly, vascular reactivity to the endothelium-independent vasodilator sodium nitroprusside (10 -9 -10 -5 mol/l) was also decreased in aldosterone-infused mice, albeit to a lesser degree than that observed with acetylcholine (Fig. 5a) .
To test whether aldosterone-mediated inhibition of G6PD activity in vivo resulted in a phenotype similar to that observed with G6PD deficiency resulting from a G6pd gene mutation, we performed the same experiments in G6PD-deficient, age-matched, male mice. In vehicle-infused G6PD-deficient mice (n ¼ 8), vascular reactivity to both acetylcholine and sodium nitroprusside was impaired (Fig. 5b) as compared to that in vehicle-infused wild-type mice (Fig. 5a) ; administration of aldosterone resulted in no further inhibition of vascular reactivity in G6PD-deficient mice (n ¼ 8).
We next investigated the relative contributions of eNOS and endothelium-derived hyperpolarizing factor (EDHF) to vascular reactivity in aldosterone-treated wild-type mice. In these studies, mesenteric vessels were superfused with N (G)-nitro-L-arginine methyl ester (L-NAME) (1 mmol/l) for 30 min, to inhibit eNOS (n ¼ 5), or L-NAME and the potassium channel antagonists TRAM-34 (1 mmol/l) and apamin (10 mmol/l) (n ¼ 5) for 15 min, to inhibit eNOS and EDHF, before exposure to acetylcholine 18 . In vehicleinfused wild-type mice (Fig. 5c) , L-NAME alone decreased the vasodilator response to acetylcholine, suggesting that most of the observed vasodilation was due to eNOS activity. In contrast, in aldosterone-infused wild-type mice (Fig. 5c) , there seemed to be a greater contribution to vasodilation by EDHF. Similar observations were made in vehicle-infused G6PD-deficient mice.
MR blockade or G6pd gene transfer restores vascular reactivity
To determine if aldosterone antagonists improve vascular reactivity in vivo by increasing G6PD activity, we treated aldosterone-infused mice with spironolactone (n ¼ 20) or vehicle (n ¼ 20). Mice were infused with aldosterone for 7 d, and decreased aorta G6PD activity (123.8 ± 12.1 versus 57.7 ± 12.9 units/6 min/mg protein, P o 0.02, n ¼ 10) was confirmed. Spironolactone (20 mg/kg/d) was then administered in the drinking water during the next 7 d of aldosterone infusion. In aldosterone-treated mice given spironolactone, there was a reduction in systolic blood pressure at 14 d, compared to that in mice that did not receive spironolactone (Fig. 6a) . In addition, spironolactone increased aorta G6PD expression (Fig. 6b) , G6PD activity (Fig. 6c) and NADPH levels (Fig. 6d) , leading to a decrease in ROS (Fig. 6e) and an increase in cGMP levels (Fig. 6f) . Furthermore, in spironolactone-treated mice, vasodilator responses to acetylcholine and sodium nitroprusside were restored to levels observed in vehicleinfused mice (Fig. 6g) .
We next determined if vascular G6PD overexpression was protective in hyperaldosteronism. In these experiments, wild-type mice were injected by tail vein with 5 Â 10 9 plaque-forming units of AdG6pd (n ¼ 24) or an empty control vector, Ad (n ¼ 24). Mouse aortic G6PD protein expression, G6PD activity and NADPH levels were increased 370%, 340% and 62%, respectively, 5 d after infection with AdG6pd compared to Ad, and remained elevated, although to a lesser extent, up to 18 d after infection ( Supplementary Fig. 8 activity and NADPH levels were decreased compared to those in vehicle-infused Ad-infected mice; in contrast, there was no observed decrease in aldosterone-treated AdG6pd-infected mice (Supplementary Fig. 8 ). In aldosterone-infused mice, there was an increase in aorta ROS formation, as measured by lucigenin chemiluminescence, in Ad-infected as compared to AdG6pd-infected mice (3.4 ± 0.1 versus 0.8 ± 0.05 nmol/l superoxide/10 min/mg protein, P o 0.01, n ¼ 4) and a decrease in cGMP levels (0.32 ± 0.1 versus 0.88 ± 0.1 pmol/mg protein, P o 0.01, n ¼ 4) (Supplementary Fig. 8 ).
Vascular reactivity experiments revealed attenuated vasodilation in response to acetylcholine and sodium nitroprusside in Ad-infected mice, an effect that was not observed in AdG6pd-infected mice ( Supplementary Fig. 8) .
DISCUSSION
These experiments demonstrate that aldosterone decreased G6PD expression in endothelial cells by increasing cAMP levels to activate PKA, which, in turn, upregulates CREM expression to inhibit CREB-DNA binding and limit transcription of G6pd. At a cellular level, decreased G6PD expression resulted in a concomitant decrease in NADPH levels to increase endothelial ROS and decrease bioavailable NO , similar to what was observed in G6PD-deficient cells. In vitro, PKA inhibition or aldosterone antagonism preserved G6PD expression to prevent the adverse sequelae of aldosterone. Similarly, overexpression of G6PD provided resistance to aldosterone-mediated increased ROS and diminished bioavailable NO . We confirmed these findings in vivo by demonstrating that pathophysiologically relevant [19] [20] [21] levels of plasma aldosterone in wild-type mice were associated with decreased vascular G6PD expression, increased ROS and decreased NO levels, similar to what is observed in G6PD-deficient mice. Functionally, elevated levels of aldosterone impaired endothelium-dependent vascular reactivity to a greater extent than did endothelium-independent vasodilation. We also found that MR blockade restored vascular reactivity by preventing decreased G6PD expression and that overexpression of G6PD was protective in a state of hyperaldosteronism.
In our study, we treated cells with relatively high concentrations of aldosterone, based on the fact that aldosterone levels as high as 10 À7 mol/l have been reported in individuals with congestive heart failure [19] [20] [21] . Furthermore, we confirmed our in vitro findings using pathophysiologically relevant levels of aldosterone in vivo. In aldosterone-infused mice, plasma aldosterone levels were increased 574% compared to vehicle-infused mice. This is well within the range by which plasma aldosterone levels are elevated in individuals with congestive heart failure as compared to healthy subjects; under these circumstances, plasma aldosterone levels have been reported to be increased up to 1,900% (ref. 21) .
Our study implicates the activation of PKA and the PKA-mediated upregulation of CREM to inhibit CREB-driven transcription as a mechanism by which hyperaldosteronism decreases G6PD expression. This is not surprising as earlier studies have shown that PKA activation modulates transcriptional functions of MR (ref. 22) and that aldosterone-mediated activation of MR may repress gene transcription 23 . However, in these studies, the role of CREM-mediated inhibition of CREB-DNA binding activity was not investigated. Under basal conditions, decreased CREB activity mediated by CREM repressor isoforms is a transient phenomenon, whereas persistent expression of CREM has been associated with pathophysiological consequences 24 . CREM is a recognized target protein of PKA, and studies have shown that inhibition of PKA results in inhibition of CREM expression 25 . Notably, prolonged increased expression of the CREM repressor isoform has been implicated in the inhibition of gene transcription in glucocorticoid-treated rats 26 and angiotensin II-treated cardiomyocytes 27 . We now show that hyperaldosteronism similarly leads to a persistent increase in CREM expression and, thereby, inhibition of G6PD expression. Accumulating evidence suggests that the adverse effects of aldosterone on vascular reactivity result from an aldosterone-induced vasculopathy characterized by increased ROS and decreased NO levels 5 . Similar to our findings, other investigators have reported an increase in ROS levels in human umbilical vein endothelial cells treated with aldosterone, which was abrogated by MR blockade 28 . Ex vivo, it has been shown that myocardial endothelial cells isolated from aldosterone-infused rats have increased indices of oxidant stress, as demonstrated by enhanced peroxynitrite formation 29 .
The effects of aldosterone on eNOS activity have been less well characterized. In human umbilical vein endothelial cells exposed to aldosterone (10 -9 -10 -7 mol/l) for 16 h and stimulated with vascular endothelial growth factor, cGMP levels and eNOS dimer/monomer ratios were decreased 28 , akin to our results. These findings were attributed to decreased levels of 5,6,7,8-tetrahydrobiopterin 28 , an eNOS cofactor whose levels are maintained by adequate G6PD activity and NADPH stores. In contrast, in a rat congestive heart failure model, eNOS expression in the aorta was decreased, an effect that was corrected by eplerenone 30 . In our experiments, we found similar levels of eNOS expression in aortas from vehicle-treated and aldosteroneinfused mice; however, eNOS activity was decreased only in aldosterone-treated mice. These differences may be explained by differences in the duration of treatment and the models used to create a state of secondary hyperaldosteronism.
We found that aldosterone antagonism restored vascular reactivity by increasing G6PD expression. It has been suggested that changes in blood pressure modulate this response [31] [32] [33] [34] ; however, comparative studies in G6PD-deficient mice suggest that changes in G6PD expression, and not blood pressure, mediate the effects of MR blockade. In C3H wild-type mice infused with angiotensin II (0.6 mg/kg/d) for 6 d, systolic blood pressure was increased, yet aorta G6PD protein levels remained similar to those observed in vehicle-infused mice 31 . Furthermore, vascular gene transfer of G6pd prevented an aldosteronemediated increase in blood pressure. These findings are supported further by clinical studies showing that impaired vascular reactivity is restored in individuals with elevated plasma aldosterone levels treated with aldosterone antagonists, independent of changes in blood pressure [32] [33] [34] . These studies suggest that the beneficial effects of aldosterone antagonism result from a mechanism that does not involve changes in systemic blood pressure, analogous to what we observed.
Our study may also explain the observed lack of benefit of aldosterone antagonism in individuals with diabetes mellitus. Study of individuals with type 2 diabetes mellitus treated with spironolactone revealed no improvement in endothelial function 35 . One potential explanation for this finding is that hyperglycemia associated with diabetes may decrease G6PD activity by a mechanism other than MR activation. Studies performed in vitro and in animal models suggest that this hypothesis has merit: BAEC exposed to elevated concentrations of glucose demonstrate decreased G6PD activity 36 , and in a diabetic rat model, renal G6PD activity is decreased substantially as compared to nondiabetic rats 10 .
Notably, our study revealed a defect in endothelium-dependent and, to a lesser extent, endothelium-independent vascular reactivity, owing to a decrease in eNOS activity. Similarly, transgenic mice that overexpress aldosterone synthase in the heart also exhibit both impaired endothelium-dependent and endothelium-independent vascular reactivity; however, the mechanism by which this occurs is unknown 37 . These findings correlate with observations made in a preliminary clinical study that investigated brachial artery vascular reactivity in G6PD-deficient individuals. In this study, 18 healthy G6PD-deficient African-American subjects with the A326G mutation were found to have impaired flow-mediated dilation 38 . We have also demonstrated previously that vascular smooth muscle cells with deficient G6PD activity have increased ROS accumulation 39 , suggesting that aldosterone may also influence G6PD activity in vascular smooth muscle cells to modulate vascular reactivity, in addition to its effects on the endothelium.
Our results suggest a new mechanism by which hyperaldosteronism impairs vascular reactivity, consonant with the concept of aldosteroneinduced vasculopathy characterized by increased oxidant stress and decreased NO bioavailability. Aldosterone-mediated inhibition of G6PD activity results in a G6PD-deficient phenotype in the vascular endothelium in the absence of a genetic cause for deficient G6PD activity. This induced phenotype is reversed by MR blockade or vascular overexpression of G6PD, resulting in resistance to the adverse sequelae of hyperaldosteronism in the vasculature. Our findings suggest further that future therapeutic intervention(s) to modulate G6PD activity may serve as a strategy to ameliorate vascular dysfunction associated with hyperaldosteronism.
METHODS
See also Supplementary Methods online.
Cell culture. Bovine aortic endothelial cells (BAEC) (Cambrex) or human coronary artery endothelial cells (Cambrex) were grown to confluence and treated with aldosterone (10 -9 -10 -7 mol/l) (Steraloids); aldosterone was dissolved in dimethylsulfoxide (10 nmol/l), which served as the vehicle control. In selected experiments, cells were co-incubated with spironolactone (10 mmol/l) (Sigma-Aldrich).
To increase G6PD expression, a recombinant adenovirus containing the rat G6pd cDNA under the control of the CMV promoter (AdG6PD) or an empty viral vector (Ad) was constructed and used as described previously 7, 17, 40 .
To isolate endothelial cells from aortas of C3H wild-type or G6PD-deficient mice, aortas were harvested from mice age 4-6 weeks, digested with collagenase (Worthington) and subjected to a double selection process by incubation with CD31 (Santa Cruz Biotechnology) and VE-cadherin (Research Diagnostics) monoclonal antibody-coated magnetic microbeads (Dynal Biotech). Cells were found to be 498% pure by uptake of 1,1¢-dioctadecyl-3,3,3¢,3¢-tetramethyl-indocarbocyanine perchlorate acetylated low-density lipoprotein (Molecular Probes) 41 .
G6PD activity and NADPH levels. G6PD activity and NADPH levels were determined according to previously published methods 6, 42 .
Immunoblotting. Proteins were size-fractionated electrophoretically using SDS-PAGE and transferred to polyvinylidene fluoride membranes. The membranes were incubated with antibodies to G6PD (Bethyl Laboratories), eNOS (Transduction Laboratories), CREB, phospho-CREB (Cell Signaling Technology) or CREM (Santa Cruz), and visualized using the ECL detection system (Amersham). To evaluate eNOS monomer-dimer formation, low-temperature PAGE was performed according to previously published methods 15, 16 .
RNA isolation, G6pd cDNA generation and northern blot hybridization. Total RNA was prepared using the RNeasy mini kit (Qiagen) and cDNA was generated using the SuperScript III One-Step RT-PCR System (Invitrogen). The following primer pairs were used: G6pd, forward (5'-ACGATGAC ACTGCCTCCTACAAGC-3¢) and reverse (5'-GCTCTTTGAAGGTGAGAAT GACGC-3¢); Crem, forward (5'-CCTCCACCAGGTGCTACAT-3¢) and reverse (5'-AGCAGCTTCCCTGTTTTTCA-3¢); Gapdh, forward (5'-GGGTCAT CATCTCTGCACCT-3¢) and reverse (5'-GGTCATAAGTCCCTCCACGA-3¢). DIG-High Prime DNA Labeling and Detection Starter Kit II (Roche) was used to label G6pd, Crem or Gapdh cDNA fragments with digoxigenin for use as probes. For northern blot analysis, 5 mg total RNA was fractionated on 1.2% formaldehyde-agarose gels and transferred onto positively charged nylon membranes (Roche). Hybridization and detection of mRNA was performed using a Digoxigenin Luminescent Detection Kit (Roche) according to the manufacturer's instructions.
Quantitative real-time PCR. Quantitative real-time PCR was performed using 20Â TaqMan G6PD or Gapdh Gene Expression Assay (Applied Biosystems) and run on Applied Biosystems 7900. Quantitation of data was performed using the comparative C T (DDC T ) method using Gapdh gene expression as an endogenous reference.
cAMP and cGMP levels. Levels of cAMP or cGMP were quantitated using an enzyme immunoassay kit (Cayman) according to the manufacturer's instructions.
Protein kinase A activity. Protein kinase A activity was measured using PepTag Non-Radioactive cAMP-Dependent Protein Kinase Assay (Promega) according to the manufacturer's instructions.
Nuclear run-on assay. Nuclear preparations were isolated using the BD TransFactor Nuclear Extraction Kit (Clontech) according to the manufacturer's instructions. Nuclear run-on assays were performed according to previously published methods 43 .
Electrophoretic mobility shift assay. Nuclear preparations were isolated using the BD TransFactor Nuclear Extraction Kit (Clontech) according to the manufacturer's instructions. An oligonucleotide probe was biotin-labeled with Biotin 3¢ End DNA Labeling kit (Pierce). The probe contained the CREB binding site (À889 to À881) from the G6pd promoter and was included using the following oligonucleotides: forward 5¢-CAGAAACAGTATGACGATAGG CAGAT-3¢ and reverse 5¢-ATCTGCCTATCGTCATACTGTTTCTG-3¢. Electrophoretic mobility shift assays were performed using the LightShift Chemiluminescent EMSA kit (Pierce) according to the manufacturer's instructions.
Chromatin immunoprecipitation assay. Chromatin immunoprecipitation assays were performed using the QuikChIP assay (Imgenex) according to the manufacturer's instructions. The G6pd primers used for PCR were forward 5¢-TGACCTCCGTGCTATTCCTC-3¢ and reverse 5¢-ACCAAACTTGACTGC GCTCT-3¢. As a specificity control, the Actb promoter was similarly amplified using the primers forward 5¢-GTAGAGCCCACCTTCCTTCC-3¢ and reverse 5¢-AGAGCGAGAGCGAGATTGAG-3¢. SGK activity. SGK activity was measured in cell homogenates using the QTL Lightspeed SGK-1 Kinase Activity assay (QTL Biosystems) according to the manufacturer's instructions.
Dichlorodihyrdofluorescein fluorescence. Nonspecific cellular ROS accumulation was measured as previously described using 20 mM 6-carboxy-2¢-7¢-dichlorodihydrofluorescein diacetate di(acetoxymethyl) ester (Molecular Probes) 7 .
GSH/GSSG levels. The ratio of glutathione (GSH) to glutathione disulfide (GSSG) was measured using the Bioxytech GSH-GSSG-412 enzymatic method (OXIS) according to the manufacturer's instructions. eNOS activity. eNOS activity was measured in intact cells without the addition of exogenous cofactors, as previously described 44 . In select experiments, eNOS activity was measured in cell homogenates with the addition of exogenous cofactors according to previously published methods 6, 7 .
In vivo aldosterone infusion. C3H wild-type male mice were obtained from Charles River and entered into studies at age 12-16 weeks. G6PD-deficient mice were maintained in a colony at Harvard Medical School and have been characterized previously 17 . The mice were fed standard chow, kept on 1% NaCl in the drinking water, and handled in accordance with US National Institutes of Health guidelines. All procedures were approved by the Institutional Animal Care and Use Committee at Boston University Medical Center and Brigham and Women's Hospital, Harvard Medical School. Alzet minipumps (Alza, Model 1002) were implanted, and mice were infused for 14 d with aldosterone (50 mg/kg/d) 45 . In selected studies, mice were treated with spironolactone, which was added to the drinking water (20 mg/kg/d) 46 .
Blood pressure. Baseline blood pressure (BP) and heart rate were determined using tail-cuff measurements (Visitech BP-2000, Visitech Systems).
Plasma aldosterone. Plasma aldosterone levels were measured by enzyme immunoassay (Cayman).
Aorta ROS generation. Aorta rings were incubated with lucigenin (5 mmol/l) and chemiluminescence was measured using a luminometer (TI-300, Turner Industries) 47 . As a second measure of ROS accumulation, unfixed aortas were immediately frozen, sectioned and incubated with 20 mmol/l dihydroethidine (Molecular Probes). Ethidium fluorescence was detected with a Zeiss LSM 510 microscope equipped with a krypton/argon laser 48 .
Vascular reactivity. Vascular reactivity of mesenteric arterioles was assessed by intravital videomicroscopy as previously described 47 . The response was expressed as percent change in vessel diameter compared with baseline.
Statistical analysis. Continuous data were expressed as mean ± s.e.m. Comparison between groups was performed by Student's paired two-tailed t-test. Two-way analysis of variance (ANOVA) was used to examine differences in response to treatments between groups, with post-hoc analysis performed by the method of Student-Newman-Keuls. P o 0.05 was considered significant.
Note: Supplementary information is available on the Nature Medicine website.
